April 20 (Reuters) - Britain's antitrust regulator said on Thursday Australian hearing device maker Cochlear's (COH) acquisition of Danish rival Demant's DEMANT.CO hearing implants business Oticon Medical could substantially reduce competition.
The Competition and Markets Authority (CMA) found a merger between two of the biggest players in the UK's hearing implant sector could lead to worse outcomes for the patients who rely on these life-changing hearing implants and higher prices for the state-owned National Health Service.
News: COH UK watchdog says Cochlear's Oticon purchase can hurt competition
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$319.42 |
Change
2.420(0.76%) |
Mkt cap ! $20.88B | |||
| Open | High | Low | Value | Volume |
| $317.80 | $319.56 | $315.50 | $38.61M | 121.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 72 | $318.37 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $319.50 | 27 | 1 |
View Market Depth
| Last trade - 16.10pm 29/07/2025 (20 minute delay) ? |
| COH (ASX) Chart |